Botulinum Toxin Type A Linked to Serum Sickness
COSMETIC botulinum toxin type A may trigger serum sickness, widening concern about delayed systemic hypersensitivity reactions.
Serum Sickness After Botulinum Toxin Type A
A new case report has highlighted a rare but clinically important immune complication following cosmetic botulinum toxin type A treatment. The report describes a 46-year-old woman with no notable medical history who had previously received fillers and neurotoxins in both the United States and Canada. After another cosmetic onabotulinumtoxin-A injection, she developed urticaria at the injection sites nine days later. Two days after that, she presented pyrexia, symmetric arthralgias, and abdominal swelling, prompting emergency evaluation.
Her initial presentation was thought to reflect a viral process, but persistent symptoms raised further concern. According to the report, allergologic assessment later supported a diagnosis of serum sickness, with albumin in the formulation considered the likely antigen. Skin testing with incobotulinumtoxin-A, a protein free neurotoxin formulation, did not produce a reaction. The patient subsequently underwent treatment with incobotulinumtoxin-A without recurrence of serum sickness.
Hypersensitivity Reactions Extend Beyond Immediate Allergy
The authors paired the case with a literature review that grouped botulinum toxin hypersensitivity reactions using the Gell and Coombs classification. Type I reactions included findings such as urticaria and angioedema, often linked to stabilizers. Type III reactions were associated with immune complex mechanisms, systemic inflammation, and secondary treatment failure. Type IV reactions included delayed, T cell mediated findings such as pruritus and induration. Within that framework, the reported serum sickness case was classified as a Type III hypersensitivity reaction.
Why Formulation Choice May Matter
The report also draws attention to formulation components as possible contributors to immunogenicity. Complexing proteins and excipients, including human serum albumin and bovine gelatin, were identified as potential triggers of immune activation. The authors suggest clinicians should maintain suspicion when delayed systemic symptoms follow cosmetic treatment, consider allergy screening and diagnostic testing when appropriate, and think carefully about formulation selection in patients with prior reactions. They also note that awareness is especially important in high volume cosmetic settings where delayed systemic complications may be overlooked.
Reference
DeLuca-Pytell D et al. Serum Sickness After Cosmetic Botulinum Toxin Type A Injections. Aesthetic Surgery Journal Open Forum. 2026;DOI:10.1093/asjof/ojag027.
Featured Image: Hedgehog94 on Adobe Stock.
